Tentative Program as at August 8, 2019

Uveitis

Chair: Ron Neumann, Israel

​

Long Term systemic effects of Immunosuppressive drugs

• Steroids

• TNF inhibitors

• Methotrexate

• Celcept

​

Discussion:

Total burden on health of systemic therapy

Topical/systemic drugs decision making

Allowing development of cataract vs. long term effects of systemic

The art of discontinuing systemic therapy

Vaccinations and epidemics in modern times and the immunosuppressed patient  

​

INFECTION

Chair: Irina Barequet, Israel

Intraocular Drug-related Complications of Endophthalmitis Prophylaxis Tat Keong Chan, Singapore

The effect of recurrent povidone-iodine usage on conjunctival flora in diabetic patients undergoing Intravitreal Injections Adi Einan Lifshitz, Israel

Diagnostic vitrectomy for suspect endopthalmitis Anat Loewenstein, Israel

LasA Protease and an adjunct enzyme-based therapy for endophthalmitis Irina Barequet, Israel

Debatae: antibiotics for intraocular infections: Yes or NO? Anat Loewenstein, Israel

​

Discusssion

​

Management of AMD

Part 1:  Present: Imaging and management in AMD

Chairs: Karina Berg, Norway, & Paolo Lanzetta, Italy

Imaging/diagnosis/follow up

OCT angiography biomarkers in neovascular (remission or activity) AMD Luis Arias Barquet, Spain

Imaging in dry AMD Alfredo Garcia-Layana, Spain

Non-exudative CNV; To treat or not? Paolo Lanzetta, Italy

Hyper- refelective foci in AMD Francesco Bandello, Italy

Discussion

When should we diagnose and treat? Prior to clinical finding?

Current practice and role of imaging in AMD

Fluorescein/Green. When is needed?

​

Treatment

Managment of polipoydal lesions (Atlantic study) Rufino Silva, Portugal

Key points of RIVAL study Karina Berg, Norway

TAE latest evidence with aflibercept (ALTAIR) Stela Vujosevic, Italy

Retreatment criteria for AMD (FLUID study) TBA

Discussion

Does the régimen matters?

Management of bilateral wet AMD

Evidence or lack of it for ideal regimen

Current evidence for TAE, addressing deteriorating lesions under TAE regimen: New loading dose? Vs. Retrieving to Previous step?

Guidance to discontinue treating, including VA as a parameter in initiation or discontinuation of therapy

​

Part 2:  What´s next? Role of New Molecules?

Chair: Barruch Kupperman, USA

Brolucizumab  Inquire with Novartis TBA

Abicipar phase III Barruch Kupperman, USA

Brimonidine in AMD Francine Behar-Cohen, France

Update on Complement inhibition results TBA

​

Discussion

The next strategic step:Improved delivery?

New Chemical/biological entities? Vs. available drugs imported from other medical fields

New non-drug strategies?

When injections become ineffective – Is there a next step?

Learning from lampalizumab failure,

Can we learn from the dementia studies failure?

​

From A to Z in Diabetic Macular Edema

Chairs: Patricia Udaondo, Spain & Stela Vujosevic, Italy

Imaging in DME

Prognostic and predictive biomarkers in DME Patricia Udaondo, Spain

Microvascular changes as predictor for DME progression Maria Cristina Parravano, Italy

How can we define chronic DME? Stela Vujosevic, Italy

​

Discussion

DME Management

Real world evidence with fluocinolone implant in DME Francesco Bandello, Italy

Long term efficacy and safety of Dexamethasone implant for DME Alfredo Adan, Spain

Real life outcomes of anti-VEGF therapy in DME: a review Paolo Lanzetta, Italy

Take home messages of latest protocols of DRCR.net (T and V) TBA

Summary of EURETINA guidelines for DME Karina Berg, Norway

Combined therapy in DME? Enrique Cervera, Spain

Discussion

​

What is next in DME?

Phase II trials that succeeded and fail for DME: angiopoietin vs Tie2 TBA

Phase 1 first-in-human study of KSI-301: a novel anti-VEGF antibody biopolymer conjugate (ABC) with extended durability J. Pablo Velazquez-Martin, USA

Drugs in pipeline for DME TBA

​

Discussion

What is expected next?

​

Central Serous Choroidopathy

Chairs: Francine Behar Cohen, France & Jose María Ruiz Moreno, Spain

CSCR classification Jay Chablani

CSCR long term visual prognosis Sarah Mrejen

CSCR and CNV : efficacy of anti-VEGF Irmela Mantel

CSCR: MRA +Dexa A. matet ou FBC

TBA Jose María Ruiz Moreno, Spain

TBA Ibraheem El Grahbli, Abu Dhabi

​

Vein Occlusion

Chairs: Albert Augustin, Germany & Alfredo García-Layana, Spain

Multimodal imaging: assesing non perfusion TBA

The LEAVO trial TBA

Long term efficacy of steroids in management of macular edema in vein Occlusion TBA

Latest evidence of anti VEGF in vein occlusion Choi-Mun Chan, Singapore

Laser in vein occlusion: when and for what? Alfredo García-Layana, Spain

Discussion

Advanced AMD

Chair: Usha Chakravarthy, UK

​

Review the pathogenesis of AMD and the pathways to CNV and GA TBA  

Examine current therapeutics and consider the long term outcomes and unmet need Usha Chakravarthy, UK

Evaluate the current therapeutic pipeline critically assessing the appropriateness of targets TBA

Designing new therapies with precision medicine in mind TBA

​

Drug Delivery

Chairs: Diane Tang Liu, USA & Uday Kompella, USA

Diabetic Macular Edema: Pathophysiology and Novel Therapeutic Agents Arup Das, USA

Microspheres as therapeutic systems to treat retinal diseases Martia Del Rocio Herrero-Varnell, Spain

Nanoformulation as intraocular drug delivery system to target the posterior segment Vittoria Raffa, Italy

TBA Mark Vezina, Canada

Targeted treatment of retinoblastoma with an oncolytic adenovirus Angel Montero Carcaboso, Spain

Extended Duration Anti-VEGF therapy: the Promises and Disappointments Michael W. Stewart, USA

Tunable duration of prolonged drug release from a novel formulation Diane Tang-Liu, USA

Biodegradable intraocular implants Uday Kompella, USA

Clearside Biomedical, Inc., VP, Discovery Viral Kansara, USA

 

Artificial Intelligence & Deep Learning: Present or future?

Chairs: Tunde Peto, UK, Leopold Schmetterer, Singapore

​

Introduction to AI and Deep learning: present and future TBA

Fight retina blindness Javier Zarranz, Spain

Home vision testing  TBA  

Analysis in DR  TBA

Future in imaging. Functional Imaging  TBA

What is the position of industry in AI? (separated? Together?) TBA

AI for glaucoma Leopold Schmetterer, Singapore

​

Discussion

​

Inhibition of Diabetic Retinopathy

Chair: Arup Das

Targeting G-proteins to inhibit Diabetic Retinopathy Renu Kowluru, USA

Kallikrein-Kinin System in Diabetic Retinopathy - Novel Target Edward Feener, USA

Targeting IL-6 Signaling to Intervene in the Progression of Diabetic Retinopathy Susanne Mohr, USA

Combotherapy of Diabetic Retinopathy: Emerging Paradigm Ashwath Jayagopal, Switzerland

 
Therapy of Retinal Angiogenesis

Chair: Arup Das

Non-coding RNA based Therapeutics Subrata Chakarabarti, Canada

Control of Retinal Angiogenesis by modification of cell membrane lipid composition and membrane fluidity Julia Busik, USA

TBA John Penn, USA

Glial influence in the pathogenesis of Diabetic Retinopathy Debasish Sinha, USA

​

GENE Therapy

Chair: TBA

Speakers: Itay Chowers, Israel, Jordi Mones, Spain, Marc de Smet, Switzerland, Usha Chakravarthy, UK,

Dave Guyer, USA

Introduction to Gene and stem cell therapy

International AMD genomic consortium.

Stem cell therapy for AMD and Retinitis Pigmentosa. Where are we?

Gene therapy for inherited retinal distrophies

Gene therapy for AMD: RGX-314

Surgeon´s view of Gene therapy approach: future of robot assistance

​

Discussion

​

Diabetic Retinopathy

Chairs: Francesco Bandello, Italy, & Rufino Silva, Portugal

​

OCT-A in patients without diabetic retinopathy Francesco Bandello, Italy

Comparison of FA and OCTA in DR Luis Arias Barquet, Spain

Ultrawidefield swept-source OCTA in DR Maria Cristina Parravano, Italy

Diabetic retinopathy treated with antiVEGF: results on clinical trials Francesco Bandello, Italy

Update on DRCR.net studies in DR TBA

Is it safe to space out injections when you are treating PDR with anti-VEGF alone? Rufino Silva, Portugal

Surgery in DME. When and How? Jose García Arumí, Spain

​

Discussion and clinical cases

​

Myopia

Chairs: Jose García Arumí, Spain & Jose Maria Ruiz-Moreno, Spain 

Update in prevention of Myopia progression TBA

Myopic maculopathy; new classification Jose Maria Ruiz-Moreno, Spain 

Factors influencing visual acuity in patients receiving antiVEGF for myopic CNV Francesco Boscia, Italy

Update on myopic CNV management Choi-Mun Chan, Singapore

When is surgery the option in myopic maculpathy? News on surgery in high myopic eyes Jose García Arumí, Spain

​

Discussion